Compass Therapeutics, Inc. (CMPX)
NASDAQ$2.46
Market Cap
$340.18M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
524 of 924
Rank in Industry
303 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CMPX Insider Trading Activity
CMPX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product …
Insider Activity of Compass Therapeutics, Inc.
Over the last 12 months, insiders at Compass Therapeutics, Inc. have bought $0 and sold $0 worth of Compass Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Compass Therapeutics, Inc. have bought $19.83M and sold $103,708 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $33,700 was made by Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) on 2023‑03‑10.
List of Insider Buy and Sell Transactions, Compass Therapeutics, Inc.
| 2023-03-10 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 10,000 0.008% | $3.37 | $33,700 | -31.33% | ||
| 2023-02-27 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.016% | $3.98 | $79,600 | -39.44% | ||
| 2023-02-15 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0153% | $3.86 | $77,200 | -38.69% | ||
| 2023-01-31 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.016% | $4.05 | $81,000 | -35.75% | ||
| 2023-01-24 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0158% | $4.19 | $83,800 | -37.29% | ||
| 2022-11-25 | Sale | Bisker-Leib Vered | Chief Operating Officer | 2 <0.0001% | $4.36 | $9 | -28.83% | |
| 2022-11-23 | Sale | Bisker-Leib Vered | Chief Operating Officer | 9,569 0.0088% | $4.30 | $41,147 | -30.00% | |
| 2022-11-22 | Sale | Bisker-Leib Vered | Chief Operating Officer | 14,929 0.0139% | $4.19 | $62,553 | -27.27% | |
| 2022-11-08 | ORBIMED ADVISORS LLC | director | 402,000 0.2887% | $3.21 | $1.29M | -25.18% | ||
| 2022-11-08 | GORDON CARL L | director | 402,000 0.2887% | $3.21 | $1.29M | -25.18% | ||
| 2022-09-07 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0148% | $3.03 | $45,450 | +4.92% | ||
| 2022-09-01 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0145% | $2.83 | $42,450 | +10.34% | ||
| 2022-08-17 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0151% | $3.05 | $45,750 | +6.67% | ||
| 2022-08-10 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0146% | $2.64 | $39,600 | +19.40% | ||
| 2022-08-01 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0145% | $2.58 | $38,700 | +21.21% | ||
| 2022-06-21 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.019% | $2.80 | $56,000 | +9.25% | ||
| 2022-06-16 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0188% | $2.34 | $46,800 | +28.74% | ||
| 2022-06-13 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 30,000 0.0339% | $2.29 | $68,700 | +57.71% | ||
| 2022-06-06 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 30,000 0.0304% | $2.83 | $84,900 | +14.08% | ||
| 2022-06-01 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0206% | $3.03 | $60,600 | +8.22% |
Total: 35
Insider Historical Profitability
12.91%
| ORBIMED ADVISORS LLC | director | 15219994 11.0064% | $37.44M | 3 | 0 | <0.0001% |
| GORDON CARL L | director | 15219994 11.0064% | $37.44M | 5 | 0 | +26.53% |
| OrbiMed Genesis GP LLC | 14690178 10.6233% | $36.14M | 2 | 0 | +76.65% | |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 6021873 4.3547% | $14.81M | 20 | 0 | +7.17% |
| Sunderland Julie | director | 2502025 1.8094% | $6.15M | 1 | 0 |
Historical Insider Profitability vs. Competitors
$99,438,720 | 81 | 6.74% | $290.44M | |
$5,911,307 | 70 | -1.38% | $309.77M | |
$109,415,500 | 33 | 18.13% | $353.41M | |
Compass Therapeutics, Inc. (CMPX) | $41,446,394 | 27 | 12.91% | $340.18M |
$24,857,912 | 21 | -35.40% | $287.11M |
CMPX Institutional Investors: Active Positions
| Increased Positions | 55 | +84.62% | 17M | +18.36% |
| Decreased Positions | 23 | -35.38% | 8M | -8.48% |
| New Positions | 19 | New | 8M | New |
| Sold Out Positions | 7 | Sold Out | 2M | Sold Out |
| Total Postitions | 97 | +49.23% | 101M | +9.88% |
CMPX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Orbimed Advisors Llc | $64,852.00 | 16.2% | 22.36M | 0 | 0% | 2024-12-31 |
| Blackstone Inc. | $29,073.00 | 7.27% | 10.03M | 0 | 0% | 2024-12-31 |
| Mpm Bioimpact Llc | $24,847.00 | 6.21% | 8.57M | +3M | +51.86% | 2024-12-31 |
| Enavate Sciences Gp, Llc | $22,586.00 | 5.64% | 7.79M | +8M | New | 2024-12-31 |
| Blackrock, Inc. | $19,974.00 | 4.99% | 6.89M | +67,163 | +0.98% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $17,385.00 | 4.34% | 5.99M | -5M | -46.14% | 2024-12-31 |
| Tang Capital Management Llc | $17,110.00 | 4.28% | 5.9M | +4M | +225.43% | 2024-12-31 |
| Rock Springs Capital Management Lp | $16,761.00 | 4.19% | 5.78M | +150,336 | +2.67% | 2024-12-31 |
| Vanguard Group Inc | $13,683.00 | 3.42% | 4.72M | +435,008 | +10.16% | 2024-12-31 |
| Fmr Llc | $11,996.00 | 3% | 4.14M | +130 | +<0.01% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.